This article is more than 5 years old. Information may no longer be current.

Trial enrollment complete for trabeculectomy adjunct drug

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CAMBRIDGE, England — A monoclonal antibody for use as an adjunct to trabeculectomy has completed enrollment in a pivotal phase 3 clinical trial, the drug’s developer announced in a press release.

Cambridge Antibody Technology has enrolled 393 patients in six European countries and South Africa in its pivotal clinical trial. Patients were randomized to compare Trabio, the company’s human anti-TGF-beta antibody, to placebo. Results from the trial are expected in early 2005, after at least a 1-year follow-up on all patients is complete.

Trabio (lerdelimumab) has shown anti-scarring effects, according to Cambridge Antibody Technology. A current European phase 2/3 trial involving 344 patients in six countries has been completed, with results expected towards the end of this year, the company said. Patient recruitment is ongoing for a U.S. trial comparing Trabio to 5-fluorouracil.

Trabio was also formerly known as CAT-152.